Avalo Therapeutics Files Q1 2025 10-Q

Ticker: AVTX · Form: 10-Q · Filed: May 12, 2025 · CIK: 1534120

Avalo Therapeutics, INC. 10-Q Filing Summary
FieldDetail
CompanyAvalo Therapeutics, INC. (AVTX)
Form Type10-Q
Filed DateMay 12, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, financials, pharmaceutical

Related Tickers: AVTX

TL;DR

Avalo Therapeutics (AVTX) filed its Q1 2025 10-Q. Financials are in.

AI Summary

Avalo Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Cerecor Inc., is based in Wayne, PA. The filing details its financial position and business operations for the first quarter of 2025.

Why It Matters

This filing provides investors with an update on Avalo Therapeutics' financial health and operational status for the first quarter of 2025, crucial for understanding the company's trajectory.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Avalo Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of Avalo Therapeutics, Inc.?

Avalo Therapeutics, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.

When was the company formerly known as Cerecor Inc.?

The company changed its name from Cerecor Inc. on November 2, 2011.

What is the business address of Avalo Therapeutics?

The business address is 1500 Liberty Ridge Drive, Suite 321, Wayne, PA 19087.

What fiscal period does this 10-Q filing cover?

This 10-Q filing covers the fiscal period ending March 31, 2025.

What is the SEC file number for Avalo Therapeutics?

The SEC file number for Avalo Therapeutics is 001-37590.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding Avalo Therapeutics, Inc. (AVTX).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing